WASHINGTON, June 2, 2021 – The Alliance for Aging Research submitted written comment to the Institute for Clinical and Economic Review (ICER) in response to their draft evidence report for aducanumab. While the Alliance does not endorse or take positions on specific drug products, the Alliance continues to express our concern regarding ICER’s methodology that systemically undervalues the lives of older individuals, persons with a disability, and those in communities of color. In the letter, the Alliance encouraged ICER to revise their value assessment methodology in order to more accurately capture the value of therapeutics to patients, caregivers, and communities that may benefit from treatments for Alzheimer’s disease. The Alliance also proposed principles for an alternative and equitable value assessment for Alzheimer’s disease treatments.
The Alliance’s comment letter can be found here.
About the Alliance for Aging Research
The Alliance for Aging Research is the leading nonprofit organization dedicated to accelerating the pace of scientific discoveries and their application to vastly improve the universal human experience of aging and health. The Alliance believes advances in research help people live longer, happier, more productive lives and reduce healthcare costs over the long term. For more than 30 years, the Alliance has guided efforts to substantially increase funding and focus for aging at the National Institutes of Health and Food and Drug Administration; built influential coalitions to guide groundbreaking regulatory improvements for age-related diseases; and created award-winning, high-impact educational materials to improve the health and well-being of older adults and their family caregivers. For more information, visit www.agingresearch.org